At the IGTP TODAY

News

Badalona Applied Research group in Oncology (B·ARGO)

- Campus Can Ruti

The IGTP presents CARE Translational Program in Cancer Research

CARE, the Translational Program in Cancer Research is the first transversal program promoted by the Germans Trias i Pujol Research Institute (IGTP), and it aims to become a bridge for researchers in the field of cancer who want to bring basic and clinical research together, so that the knowledge and the tools generated in the laboratory can benefit the patient.

- Research

IV Workshop on translational research on urological tumours. From the laboratory to clinical practice

On 11-12 November the IV Workshop on translational research on urological tumours: from the laboratory to clinical practice took place at the Badalona Conference Centre (BCIN). They were jointly organized by the Germans Trias i Pujol Research Institute (IGTP) and the Badalona Applied Research Group in Oncology (B·ARGO), and the Institut Català d'Oncologia (ICO) and are scientifically accredited by SEOM and SOGUG.

- Research

A multi-disciplinary team identifies new ways to classify glioblastoma patients and points to new therapies

A consortium led by Dr Carmen Balaña of the Badalona Applied Research Group in Oncology (B-ARGO Group) of the Catalan Institute of Oncology (ICO) Badalona at the Germans Trias i Pujol Research Institute (IGTP) has published two papers that indicate better ways to stratify glioblastoma patients, which could allow doctors to make predictions about prognosis and make better decisions about which treatments to apply.

- Research

Researchers discover a mechanism that can increase survival in patients with advanced prostate cancer

Researchers from the IGTP, ICO and IDIBELL have observed that advanced prostate cancer cells that have become resistant to standard treatment have an Achilles heel that can be attacked with a combination of chemotherapies .

Validation of  this cellular mechanism would permit identification  of patients who have developed resistance to standard treatments and the implementation of more personalized medicine for prostate cancer.

- Research

Funding for a project focussed on the response to immunotherapy for the treatment of colorectal cancer

This year the Fundación Mutua Madrileña has allocated 2.3 million euros for financing medical research in Spain. Four of the 21 clinical studies benefiting are projects being carried out in Catalan research centres, which will receive a total of 540,000 euros. One of these is being led by the Germans Trias I Pujol Research Institute (IGTP) and coordinated between four groups of the Programme for Predictive and Personalized Medicine of Cancer (IGTP-PMPPC).